Thank you to the many front-line workers and organizations working tirelessly to help in these difficult days. While we are still actively recruiting for the TALLY study, please be aware that our sites may be particularly busy at this time or adjusting their usual practice to better protect the health and safety of site staff and study participants. Please find updates on Biogen’s response to COVID-19 here.

Please follow your local public health department’s guidance for reducing the risk of infection with COVID-19. You can also visit the Centers for Disease Control and Prevention and World Health Organization websites for more information.

Logo copy here

It's not positive. It's not negative. It's cognitive.

A new clinical trial for cognitive impairment
associated with schizophrenia.

While therapies exist to address some symptoms of schizophrenia, there are currently no approved medications for cognitive impairment associated with schizophrenia (CIAS). We’re researching potential ways to change this.

That’s why we’re conducting the TALLY clinical trial. We want to see if a new investigational drug could potentially address this unmet need, and impact things like memory, attention and problem solving.

Do you have a patient or know someone who might want to participate in this research? Are you living with schizophrenia and want to know more? See who could qualify by taking our short eligibility test.

Biogen 225 Binney Street Cambridge, MA 02412
Privacy policy
Biogen-04403 263CS201_TALLYWebsite_v3_08Jan20
  • A
  • A
  • A
High-contrast Proceed